Thank you for keeping us abreast on PREPARE RCT (PRevention Using EPA Against coloREctal).
As a reminder, Amarin’s Form 10-K 2022 for the year ending December 31, 2021 asserts that the Company "owns" "one additional patent related to the use of VASCEPA to treat prostate cancer with a term that expires in 2037."